Today's Date: August 2, 2021
CrossFit Crowns Fittest Men and Women From 24 Age Group & Adaptive Divisions at 2021 NOBULL CrossFit Games   •   Chinese Giants GAC and Huawei Will Work Together to Develop a Smart SUV   •   A Career Dealing with Death and Dying Gives You a Unique Perspective on Life   •   Aleada’s Elena Elkina Leads Virtual Panel for Women in Security and Privacy (WISP) Session on Recruiting Diversity for Inf   •   Meet Margaret Darawanda, a Dedicated Akashinga Ranger, on World Ranger Day.   •   Bobbie Evolves the Conversation Around How We Feed Our Babies to be More Inclusive of All Parents   •   STAPLES Center Partners With County of Los Angeles and Fulgent to Provide Free COVID-19 Vaccinations to Community and Concertgoe   •   Port Houston Reopens Container Terminals   •   P&G Announces Fourth Quarter and Fiscal Year 2021 Results   •   Gurucul CEO Saryu Nayyar Named Winner of the Top 10 Women in Cybersecurity for 2021 by Cyber Defense Magazine   •   Greenberg Traurig and ROMBA Host LGBT+ Workplace Management Webinar   •   Fresh Air Miracle for Classical Tahoe 2021 Festival and Music Institute July 30 - August 15   •   Statement by the Prime Minister on Emancipation Day   •   Jon R. Moeller Elected P&G President and Chief Executive Officer   •   ComEd and Metropolitan Mayors Caucus Offer Grants to Illuminate Community Holiday Lighting Events   •   The State of Black Business: New Survey Finds Progress, Challenges   •   Healthline Media Deepens Commitment to Black Mental Health with Investment in BEAM Black Wellness Innovation Fund   •   Post COVID-19 Security Services Market Procurement Research Report | SpendEdge   •   Minister Chagger makes statement on first National Emancipation Day   •   The World Gave Her Nothing to Work With, But Her Lord Gave Her Everything
Bookmark and Share

FDA Approves First Oral Blood Thinning Medication for Children

FDA Approves First Oral Blood Thinning Medication for Children

PR Newswire

SILVER SPRING, Md., June 21, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days. The FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.

In addition, Pradaxa was approved in capsule form to treat blood clots in patients eight years and older with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days, and to prevent recurrent clots in patients eight years and older who completed treatment for their first venous thromboembolism.

Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth; the only other approved blood thinning medication for children is given by injection. Pradaxa was originally approved in 2010 to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

"The FDA is committed to helping our youngest patients with serious medical conditions have treatments that are relatively easy to take," said Ann Farrell, M.D., director of the Division of Non-Malignant Hematology in the FDA's Center for Drug Evaluation and Research. "With today's approval of Pradaxa, pediatric patients have another therapeutic option to treat and prevent potentially deadly blood clots."

Blood clots can be a serious problem in children as well as adults. Children are most at risk for blood clots if they have cancer, congenital heart disease, a central venous catheter, or are admitted to an intensive care unit. Venous thromboembolism can lead to complications, including swelling and discomfort near the clot, chest pain, lung damage, and even death. 

The safety and efficacy of Pradaxa for treating blood clots in patients younger than 18 was evaluated in one study of 267 pediatric patients. In this open-label study, patients were randomly assigned to receive either Pradaxa or standard of care. The study compared the two groups for the number of patients who met the composite endpoint (a combination of multiple clinical endpoints), which meant that they had not died from a blood clot, their blood clots had completely resolved, and they had no additional blood clots. Results showed that 81 (45.8%) of the 177 people taking Pradaxa met the composite endpoint compared to 38 (42.2%) of the 90 patients who received standard of care.

The safety of Pradaxa to prevent recurrent blood clots in the same pediatric population was evaluated in an open-label, single-arm study in 214 patients with a history of blood clots. The primary endpoints of the study were recurrence of blood clots, major and minor bleeding events, and death (both overall and related to blood clots). The safety of Pradaxa with long-term use was similar to the previously discussed study. Recurrence of blood clots occurred in three patients (1.4%), which was comparable to prior standard-of-care treatments.

The most common side effects of Pradaxa include digestive system symptoms and bleeding. Pradaxa can cause serious and fatal bleeding. Pradaxa is not recommended for patients with bioprosthetic heart valves or triple-positive antiphospholipid syndrome. Pradaxa has a boxed warning cautioning that early treatment discontinuation may increase the risk of blood clots and that blood accumulation within parts of the spinal cord (spinal or epidural hematomas) in patients undergoing spinal procedures may cause serious side effects.

Pradaxa received a priority review designation for this indication.

The FDA granted the approval of Pradaxa to Boehringer Ingelheim Pharmaceuticals, Inc.

Media Contact: Chanapa Tantibanchachai, 202-384-2219

Consumer Inquiries: Email or 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-approves-first-oral-blood-thinning-medication-for-children-301316705.html

SOURCE U.S. Food and Drug Administration



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News